Lissi Hansen1, Michael F Chang2, Shirin Hiatt3, Nathan F Dieckmann3, Karen S Lyons4, Christopher S Lee4. 1. School of Nursing, Oregon Health and Science University, 3455 S.W. U.S. Veterans Hospital Rd., Portland, OR, 97239, USA. hansenli@ohsu.edu. 2. Gastroenterology and Hepatology, VA Portland Health Care System, 3710 S.W. U.S. Veterans Hospital Rd., Portland, OR, 97239, USA. 3. School of Nursing, Oregon Health and Science University, 3455 S.W. U.S. Veterans Hospital Rd., Portland, OR, 97239, USA. 4. William F. Connell School of Nursing, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, 02467, USA.
Abstract
BACKGROUND: Studies assessing multiple symptoms and the distress of these symptoms in decompensated cirrhosis are lacking. AIMS: The aims of this study were to assess symptom prevalence and distress among patients with decompensated cirrhosis and to describe medical management of the most prevalent symptoms. METHODS: Patients were recruited from hepatology clinics within two health-care systems. Eligibility criteria included a model for end-stage liver disease (MELD-Na) score ≥15. Patients completed the Condensed Memorial Symptom Assessment Scale and Patient Health Questionnaire. Comparative statistics were used to analyze the cross-sectional survey data. RESULTS: Of the sample (n = 146), most patients were Child-Turcotte-Pugh (CTP) class B (49.7%) and C (46.2%). Mean age was 56.5 years, 65.1% were male, and 88.4% were white. Average MELD-Na score was 19.1 ± 4.5. The most prevalent symptoms were lack of energy and feeling drowsy while the most distressing were lack of energy and difficulty sleeping. Only 24 patients (16.4%) were treated for their difficulty sleeping with sleep medication. Importantly, those prescribed sleep medications had similar distress (3.9 ± 1.2 vs. 3.5 ± 1.2, p = 0.229) compared with patients not prescribed sleep medications. Opioids were prescribed to 57 (39.0%) patients; antidepressants to 34 (23.3%). Forty patients (27.4%) who reported moderate or greater depression were not prescribed an antidepressant. CONCLUSIONS: The study highlights the multiple symptoms and distress experienced by patients with decompensated cirrhosis, and the need for improved medical management by health-care providers through enhanced awareness and attention to these complex symptoms. Future research should focus on improvements in symptom management.
BACKGROUND: Studies assessing multiple symptoms and the distress of these symptoms in decompensated cirrhosis are lacking. AIMS: The aims of this study were to assess symptom prevalence and distress among patients with decompensated cirrhosis and to describe medical management of the most prevalent symptoms. METHODS: Patients were recruited from hepatology clinics within two health-care systems. Eligibility criteria included a model for end-stage liver disease (MELD-Na) score ≥15. Patients completed the Condensed Memorial Symptom Assessment Scale and Patient Health Questionnaire. Comparative statistics were used to analyze the cross-sectional survey data. RESULTS: Of the sample (n = 146), most patients were Child-Turcotte-Pugh (CTP) class B (49.7%) and C (46.2%). Mean age was 56.5 years, 65.1% were male, and 88.4% were white. Average MELD-Na score was 19.1 ± 4.5. The most prevalent symptoms were lack of energy and feeling drowsy while the most distressing were lack of energy and difficulty sleeping. Only 24 patients (16.4%) were treated for their difficulty sleeping with sleep medication. Importantly, those prescribed sleep medications had similar distress (3.9 ± 1.2 vs. 3.5 ± 1.2, p = 0.229) compared with patients not prescribed sleep medications. Opioids were prescribed to 57 (39.0%) patients; antidepressants to 34 (23.3%). Forty patients (27.4%) who reported moderate or greater depression were not prescribed an antidepressant. CONCLUSIONS: The study highlights the multiple symptoms and distress experienced by patients with decompensated cirrhosis, and the need for improved medical management by health-care providers through enhanced awareness and attention to these complex symptoms. Future research should focus on improvements in symptom management.
Authors: Lissi Hansen; Karen S Lyons; Nathan F Dieckmann; Michael F Chang; Shirin Hiatt; Emma Solanki; Christopher S Lee Journal: Res Nurs Health Date: 2017-06-30 Impact factor: 2.228
Authors: Elliot B Tapper; Fasiha Kanwal; Sumeet K Asrani; Chanda Ho; Nadia Ovchinsky; John Poterucha; Avegail Flores; Judith E Smith; Victor Ankoma-Sey; Bruce Luxon; Michael L Volk Journal: Hepatology Date: 2018-04-19 Impact factor: 17.425
Authors: Fliss E M Murtagh; Julia M Addington-Hall; Polly M Edmonds; Paul Donohoe; Irene Carey; Karen Jenkins; Irene J Higginson Journal: J Palliat Med Date: 2007-12 Impact factor: 2.947
Authors: Lissi Hansen; Michael F Chang; Shirin Hiatt; Nathan F Dieckmann; Arnab Mitra; Karen S Lyons; Christopher S Lee Journal: Clin Gastroenterol Hepatol Date: 2021-11-20 Impact factor: 13.576
Authors: Nneka N Ufere; Jan Hinson; Simon Finnigan; Elizabeth E Powell; John Donlan; Cathy Martin; Phil Clark; Patricia C Valery Journal: Curr Treat Options Gastroenterol Date: 2022-04-19